Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery

Sponsor
Grewal Eye Institute
Study ID
NCT00468429
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study analyzes the safety and efficacy of off-label Subconjunctival Injection of bevacizumab (Avastin) versus 0.02% mitomycin C (MMC) for preventing bleb failure following glaucoma filtration surgery.

Key Dates

First listed
May 2, 2007
Start date
May 31, 2007
Status verified
Jun 2007
Completion
Dec 31, 2007

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

IOP < 18mmHg without anti- glaucoma medications at 6 months follow up after surgery or at least a 20% reduction from baseline IOP. [ Time Frame: 6 months ]

Central Contacts

Related Studies